Proactive Investors - Run By Investors For Investors

FSD Pharma unveils strategic business developments; appoints interim CEO

Dr. Raza Bokhari, the executive co-chairman, has been appointed as interim CEO with immediate effect
Boardroom
The firm announced some leadership changes

FSD Pharma Inc (CSE: HUGE) (OTCQB: FSDDF) announced some leadership changes and said it had finished a strategic assessment of the group.

Dr. Raza Bokhari, the executive co-chairman, has been appointed as interim CEO with immediate effect. His appointment follows the termination of Rupert Haynes.

In addition, to  assist with the search for a pharmaceutical executive and other senior executives to lead FSD Pharma’s pharmaceutical business practices, the company has hired Greg Button, Global Head of HealthCare recruiting at Korn Ferry, a leading global organizational consulting firm.

FSD also announced the termination of a definitive agreement with Auxly Cannabis Group Inc effective from February 6, 2019.

Under the terms of the agreement dated March 3, last year. Auxly was obligated to develop all aspects of the company’s cannabis cultivation facility in mutually agreed upon staged phases.

“We are taking these momentous steps to unlock shareholder value and re-energize execution of our company’s vision” said Dr. Bokhari, executive co-chairman and interim CEO of FSD Pharma.

“The board believes the company has unique and invaluable assets and is taking appropriate actions that will support long-term positive cash flow and shareholder value.”

Yesterday, the company said that it and Solarvest BioEnergy Inc (CVE: SVS), a tech company, which has developed an algal-baseD production platform capable of producing health products, signed a non-binding letter of intent (LOI).

The pair aim to enter into a definitive agreement, under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids.

The parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids.

The parties also aim to establish a joint scientific review committee, comprised of representatives from both parties, to assess the progress of the CBD research project against these budgets and timelines.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full HUGE profile View Profile

FSD Pharma Timeline

Related Articles

Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis plant
March 08 2019
The Vancouver company's recent move into Jamaica, which covers the acquisition of 145 acres of cultivation property, will pave the way for the development of cannabis brands for the island nation
1541165310_canadian-flag-1.jpg
November 02 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use